Advertisement
open access
Medical Conferences
Conference Reports
2024 Medicom Conference Planning
Conference Proceedings
Disease Areas
Medical News
Multimedia
Podcast Channel
Videos
Webinar
About
Conference Proceedings
2024 Medicom Conference Planning
Home
>
Gastroenterology
>
ECCO 2019
ECCO 2019
European Crohn's and Colitis Organisation
6–9 March 2019,
Copenhagen, Denmark
Read the full Report (e-book)
Table of Contents
Colophon
Table of Contents
Featured articles
Letter from the Editor
Editor
Dr Triana Lobatón, Ghent University Hospital, Belgium
Interview with Prof. Janneke van der Woude
Expert
Prof. Janneke van der Woude, Erasmus University Medical Center, the Netherlands
New Compounds: Study Results
HDAC6 inhibition by CKD-506
Selective oral sphingosine 1-phosphate receptor modulator amiselimod
Pan-Janus kinase inhibitor TD-1473
Selective sphingosine-1-phosphate receptor modulator etrasimod
p19-Directed IL-23 antibody mirikizumab
OPERA II study: MAdCAM-1 antibody SHP647
Upadacitinib: data from U-ACHIEVE and CELEST
ABX464: HIV drug tested in ulcerative colitis
Cyclosporine: novel low-dose, controlled-release formulation
Short-term and Long-term Treatment Results
The right drug for the right patient
Presented By
Dr Charlie Lees, Western General Hospital, United Kingdom
Vedolizumab superior to adalimumab in ulcerative colitis
Presented By
Dr Stefan Schreiber, University-Hospital Schleswig-Holstein, Germany
Vedolizumab: Results from the GEMINI programme
Ustekinumab as maintenance therapy and with shortened interval
Tofacitinib: Results from the OCTAVE open-label studies
Safety of thiopurine + allopurinol vs thiopurine monotherapy
Limited long-term effectiveness and safety of tacrolimus in ulcerative colitis
Complementary and Alternative Medicine
Topical review
Presented By
Dr Joana Torres & Prof. Stephan Vavricka
Complementary and alternative medicine associated with chronic fatigue and lower QoL
Crohn’s disease exclusion diet + partial enteral nutrition in paediatric Crohn’s disease
Presented By
Dr Arie Levine, Mount Saint Vincent University, Canada
Microbial composition and psychological wellbeing
Presented By
Dr Luc Biedermann, University Hospital Zurich, Switzerland
Glycans as novel immunomodulators in inflammatory bowel disease
Remission
Early remission of Crohn’s disease prevents progression
Presented By
Dr Thierry Yzet, Amiens University Hospital, France
Histological remission predicts relapse-free survival in ulcerative colitis
Proactive adalimumab trough measurements
Presented By
Dr Amit Assa, Schneider Children’s Hospital, Israel
Relapse after withdrawal of thiopurines
Observational Studies
The costs and benefits of biologicals
Presented By
Dr Johan Burisch, Frederiksberg Hospital, Denmark
Efficacy and safety of biosimilars
Infliximab retreatment in luminal Crohn’s disease
IBD risk of treatment with IL-17 antagonists
Presented By
Dr Wolfgang Eigner, Medical University of Vienna, Austria
Basic and Preclinical Research
Pathogenesis
Presented By
Dr Jiangwen Zhang, Dr V. Garlatti
Immune cells and microbes: a happy marriage?
Presented By
Dr Loris Lopetuso, Catholic University of the Sacred Heart, Italy
Moving towards new therapeutic options
Genetics
Novel host-microbiome interactions in inflammatory bowel disease
Molecular effects of ustekinumab
Gene expression signature predicts non-response
ZNF133 associated with infliximab response
Network analysis of GWAS